What invalidating breast cancer gene patents implies dating recourse suggest link

In addition, the present invention includes a nucleic acid molecule encoding any fragment of Ras comprising a useful, any one or more of the mutations of these mutations in any of the screening, diagnostic, or therapeutic application.

In one aspect, the nucleic acid sequence level of a nucleic acid sequence encoding the mutated Ras protein is brought into contact with the nucleic acid isolated from the selective primer or probe and the test sample which binds to the nucleic acid sequence encoding the mutated Ras protein, encoding the mutated Ras protein It is determined by detecting whether the coupling by which the primer or probe.

In one aspect, the amino acid sequence comprising an amino acid mutation at a position selected from the wild-type K-ras, N-ras or H-ras in connection with protein 12 times the wild-type preparation, 13 and the group consisting of 59 times and 61 times , further comprises at least 5 contiguous amino acid residues of the mutated Ras protein.

The embodiments In one aspect, the amino acid sequence is the wild-type K-ras, N-ras or H-ras protein with regard to five or more consecutive amino acid residues of the mutant Ras proteins comprising an amino acid mutation at position 12 times the wild-type compared to to include an additional.

In one aspect, the amino acid sequence is the SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11 or SEQ ID NO: for the glutamic acid of No.

76 position of the 13 non-SEQ ID NO: by substitution of the glutamic acid amino acid 3, any one of SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11 or SEQ ID NO: 13 and one is differentiated.

Search for what invalidating breast cancer gene patents implies:

what invalidating breast cancer gene patents implies-34

In a further aspect, the tumor antigen is (a) the amino acid residues of the 12 times the wild-type Ras protein mutated position contrast, the peptide including at least 8 to 16-position of the Ras protein;본 발명의 또 다른 구체예는 Ras 아미노산 서열 중 73번 위치에서의 프롤린(P73), 74번 위치에서의 트레오닌(T74), 75번 위치에서의 글라이신(G75), 77번 위치에서의 글라이신(G77) 및/또는 78번 위치에서의 페닐알라닌(F78)이 돌연변이된, Ras (H-Ras, N-Ras 또는 K-Ras)를 코딩하는 핵산 서열의 5개 이상의 연속 아미노산을 포함하는 단리된 핵산 분자에 관한 것이다.

Leave a Reply

Your email address will not be published. Required fields are marked *

One thought on “what invalidating breast cancer gene patents implies”